Pioneering new ways to anti-infective drugs

Athelas SA
rue Lombard 15
1205 Genève

Auf Karte anzeigen
Öffnungszeiten
MO: 08:00 - 17:00
Firmenbeschrieb
Athelas SA is a drug discovery company developing novel anti-infective drugs to treat life-threatening bacterial infection. With its unique capacity to target bacterial mechanisms never previously used to develop anti-bacterial drugs, Athelas opens the way to the development of the anti-infectives of tomorrow.

„Für unsere Kunden sind wir einzigartig, weil Athelas has a unique capacity to target bacterial mechanisms never previously used leading to totally novel anti-infective drugs with the advantages of circumventing bacterial resistance and toxicity issues linked to conventional antibiotics“

Gründungsjahr
2002
 
Rechtsform
-
 
Anzahl Mitarbeiter
-
 
Umsatz
-
 
MwSt-Nr
-
 
Handelsregister
-
 
Sprachen
Français, English
 
Zielmärkte
-
 


Bilder
Marktleistungen
  • DiVi proprietary drug discovery platfrom
    Athelas' proprietary core technology, named DiVi (patent pending), is a unique, integrated cell-based approach to anti-infective drug discovery. It enables the fast and effective identification and optimization of drug candidates acting on bacterial mechanisms essential for the onset, spreading and maintenance of the infection in vivo, and that have never been exploited before in the anti-bacterial field. These compounds affect bacterial viability and pathogenicity only within the host during infection, but not in vitro, and are targeting bacterial mechanisms of action entirely different from current antibiotics. The infections will be cured, while circumventing bacterial resistance and toxicity issues linked to conventional antibiotics.
  • Novel anti-infectives compounds
    Athelas focuses on the development of bacterial inhibitors of pathogenicity against relevant human pathogens, with a particular emphasis for indications in which conventional antibiotic treatments fail, such as antibiotic-resistant nosocomial infections, or chronic infections, as well as in cases where preventive and premptive treatments would significantly improve the patient's outcome. Athelas ' drugs will treat Gram - and or Gram+ bacterial infections. Both synthetic and natural compounds are screened via DiVi drug discovery platform for potential anti-bacterial activity.
  • Pathogenicity gene targets
    Bacterial genes identified through DiVi are validated in relevant animal model of infection, and the most promissing are selected for target-based drug discovery programs.
Kernkompetenzen
Noch keine Kernkompetenzen
Kooperationspartner
  • Genedata SA
    A partnership with Genedata AG (Basel) was established to exploit the wealth of genetic information generated by our gene discovery and validation program. Athelas has access to Phylosopher, a state-of-the-art computational system for the integrated analysis of functional genomics data that supports all biology-driven aspects of today's drug discovery.
    genedata.com
  • Merlion Pharmaceutical
    Athelas and MerLion Pharmaceuticals have entered into a collaboration to identify and develop natural compounds
    merlionpharma.com
Kundengruppen
Noch keine Kundengruppen
Referenzkunden


Zertifikate
Noch keine Zertifikate
Mitgliedschaften
Noch keine Mitgliedschaften
Links
Noch keine Links
Eintrag erstellt: 11.06.2004, Letzte Änderung: 27.09.2004